Search Result

Results for "

Thrombin receptors

" in MCE Product Catalog:

By Targets:	Protease Activated Receptor (PAR) (19) Thrombin (3) 5-HT Receptor (2) Apoptosis (2) Glycoprotein VI (2) NO Synthase (2) PKC (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (19) Infection (1) Inflammation/Immunology (10)

Inhibitors & Agonists

Peptides

Targets Recommended: Thrombin Protease Activated Receptor (PAR)

Cat. No.	Product Name	Target	Research Areas

HY-P2518

Protease-Activated Receptor-1, PAR-1 Agonist	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.

HY-P0078

TRAP-6 PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective *protease activating receptor* 1 (PAR1) agonist. TRAP-6 activates human platelets via the thrombin receptor**. TRAP-6 shows no activity at PAR4.

HY-150790

BMS-986141	Protease Activated Receptor (PAR)	Cardiovascular Disease
BMS-98614 is an orally active, selective thrombin receptor *protease-activated receptor-4 (PAR-4)* antagonist with an IC₅₀ value of 0.4 nM. BMS-98614 has excellent antithrombotic effect.

HY-18200

Atopaxar E5555; ER-172594-00	Protease Activated Receptor (PAR)	Cardiovascular Disease
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor *protease-activated receptor-1 (PAR-1)* antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease.

HY-18200B

Atopaxar hydrobromide E5555 hydrobromide; ER 172594-06	Protease Activated Receptor (PAR)	Cardiovascular Disease
Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor *protease-activated receptor-1 (PAR-1)* antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease.

HY-P1000

TRAP-14
SFLLRNPNDKYEPF
Thrombin Cardiovascular Disease

TRAP-14 (SFLLRNPNDKYEPF) is a synthetic thrombin receptor agonist peptide.

TRAP-14 SFLLRNPNDKYEPF	Thrombin	Cardiovascular Disease
TRAP-14 (SFLLRNPNDKYEPF) is a synthetic *thrombin* receptor agonist peptide.

HY-10119

Vorapaxar SCH 530348	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor *protease-activated receptor* (PAR-1) antagonist (K_i*=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin* receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.

HY-10119A

Vorapaxar sulfate SCH 530348 sulfate	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor *protease-activated receptor* (PAR-1) antagonist (K_i*=8.1 nM). Vorapaxar sulfate inhibits thrombin* receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.

HY-P2321

TRAP-6 amide
Protease Activated Receptor (PAR) Inflammation/Immunology

TRAP-6 amide is a PAR-1 thrombin receptor agonist peptide.
HY-P2321A

TRAP-6 amide TFA
Protease Activated Receptor (PAR) Inflammation/Immunology

TRAP-6 amide TFA is a PAR-1 thrombin receptor agonist peptide.

TRAP-6 amide	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 amide is a PAR-1 thrombin receptor agonist peptide.

TRAP-6 amide TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 amide TFA is a PAR-1 thrombin receptor agonist peptide.

HY-108555

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide **thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1** antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM..

HY-P1261

Parstatin(mouse)	Protease Activated Receptor (PAR)	Inflammation/Immunology Cardiovascular Disease
Parstatin(mouse), a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.

HY-P1262

Parstatin(human)	Protease Activated Receptor (PAR)	Inflammation/Immunology Cardiovascular Disease
Parstatin(human), a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.

HY-P1262A

Parstatin(human) TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology Cardiovascular Disease
Parstatin(human) TFA, a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.

HY-P1261A

Parstatin(mouse) TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology Cardiovascular Disease
Parstatin(mouse) TFA, a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.

HY-P1536

Thrombin Receptor Activator for Peptide 5 (TRAP-5)	Protease Activated Receptor (PAR)	Cardiovascular Disease
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or *Proteinase Activated Receptor* 1** (1-5), used in the research of coronary heart disease (CHD).

HY-P0316

TP508	Thrombin NO Synthase	Cardiovascular Disease
TP508 is a 23-amino acid nonproteolytic *thrombin* peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 activates endothelial cells and stem cells to revascularize and regenerate tissues.

HY-P0316A

TP508 TFA	Thrombin NO Synthase	Cardiovascular Disease
TP508 TFA is a 23-amino acid nonproteolytic *thrombin* peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.

HY-P2518A

Protease-Activated Receptor-1, PAR-1 Agonist TFA	Protease Activated Receptor (PAR)	Cancer
Protease-Activated Receptor-1, PAR-1 Agonist TFA is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist TFA corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.

HY-14993

SCH79797	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 is a highly potent, selective nonpeptide *protease activated receptor* 1 (PAR1)** antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.

HY-14994

SCH79797 dihydrochloride	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 dihydrochloride is a highly potent, selective nonpeptide *protease activated receptor* 1 (PAR1)** antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.

HY-128345

UDM-001651	Protease Activated Receptor (PAR)	Cardiovascular Disease
UDM-001651 is a potent, selective, and orally bioavailable *protease-activated receptor* 4 (PAR4) antagonist (IC₅₀=4 nM; K_d=1.4 nM). UDM-001651 shows antiplatelet potency (IC₅₀*=25 nM) in a γ-thrombin*-induced platelet-rich plasma aggregation assay (γ-Thr PRP).

HY-107613A

R 59-022 hydrochloride DKGI-I hydrochloride; Diacylglycerol kinase inhibitor I hydrochloride	PKC 5-HT Receptor	Cancer Infection Inflammation/Immunology
R 59-022 (DKGI-I) hydrochloride is a DGK inhibitor (IC₅₀: 2.8 µM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils.

HY-107613

R 59-022 DKGI-I; Diacylglycerol kinase inhibitor I	PKC 5-HT Receptor	Inflammation/Immunology
R 59-022 (DKGI-I) is a DGK inhibitor (IC₅₀: 2.8 µM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils.

HY-115912

GPVI antagonist 3	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC₅₀ values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.

HY-115911

GPVI antagonist 2	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC₅₀ values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent.